Company Spotlight: Ultromics EchoGo Amyloidosis (1.0) - Finding Disease in the Echo

Podcast: AI in Medicine - curated summaries making complex issues easy to understand · Mike Rawson

Opublikowano: 2026-10-22

We unpack the FDA 510(k) summary for EchoGo Amyloidosis 1.0, an AI screening tool by Ultromics designed to detect cardiac amyloidosis from routine echocardiograms. We break down its performance numbers, how it handles uncertain data, and the demographic gaps in its testing dataset. Key points EchoGo Amyloidosis 1.0 is an AI tool cleared to screen for cardiac amyloidosis in heart failure patients aged 65 and over.It analyzes a standard apical four-chamber 2D echocardiogram without contrast.In a retrospective testing dataset of 1,164 patients, it achieved 84.5% sensitivity and 89.7% specificity.The software rejects 14.0% of scans as too uncertain to classify, which...